<DOC>
	<DOCNO>NCT02814643</DOCNO>
	<brief_summary>This randomize , double-blind , parallel group , placebo-controlled study design investigate potential effect fix dose benralizumab administer subcutaneously ( SC ) antibody responses follow seasonal influenza virus vaccination</brief_summary>
	<brief_title>Study Evaluate Potential Effect Benralizumab Humoral Immune Response Seasonal Influenza Vaccination Adolescent Young Adult Patients With Severe Asthma</brief_title>
	<detailed_description>This study design investigate potential effect benralizumab antibody response seasonal influenza virus vaccine patient 12-21 year age asthma . Benralizumab give subcutaneously ( SC ) Weeks 0 , 4 , 8 week , time benralizumab level reach steady state . Patients receive 1 dose intramuscular ( IM ) seasonal influenza virus vaccine Week 8 sample draw Week 8 Week 12 measure antibody response influenza virus</detailed_description>
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Female male patient age 12 21 year , inclusive , time Visit 1 Weight ≥40 kg Documented history current treatment Inhaled corticosteroid ( ICS ) longacting β2 agonist ( LABA ) Morning prebronchodilator force expiratory volume 1 second ( FEV1 ) &gt; 50 % predict Visit 1 Visit 2 . Airway reversibility ( FEV1 &gt; 12 % 200 ml ) demonstrate Visit 1 Visit 2 use Maximum Postbronchodilator Procedure OR Airway reversibility document previous 12 month prior Visit 1 An exacerbation , 1 , require oral corticosteroid previous year OR Any condition assess patient recall previous 24 week Clinically important pulmonary disease asthma Known history allergy reaction Investigational Product formulation influenza vaccine Receipt influenza vaccine within 90 day prior randomization Poorly control asthma screen period require treatment oral corticosteroid hospitalization/emergency room visit treatment asthma Acute illness evidence significant active infection know influenza infection current flu season</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>21 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Male female adolescent patient</keyword>
	<keyword>severe asthma</keyword>
</DOC>